Does Blue Cross Blue Shield of Minnesota Cover Tirzepatide (Mounjaro)?

What Tirzepatide Is and Why Coverage Decisions Are Complicated

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA approved it in May 2022 under the brand name Mounjaro for adults with type 2 diabetes as an adjunct to diet and exercise, and in November 2023 under the brand name Zepbound specifically for chronic weight management in adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. FDA approval letter for Mounjaro covers the diabetes indication; FDA approval for Zepbound covers the obesity indication.

The same active molecule carries two different brand names, two different FDA-labeled indications, and two entirely separate coverage pathways inside a single insurance plan. That split is the root cause of most patient confusion. A member with type 2 diabetes who receives a Mounjaro prescription faces different formulary rules than a member without diabetes who receives a Zepbound prescription, even though both inject the identical drug at the same doses.

The clinical evidence behind these approvals is strong. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks compared with 3.1% in the placebo group (NEJM, 2022). The SURPASS-2 trial (N=1,879) compared tirzepatide head-to-head with semaglutide 1 mg and found significantly greater HbA1c reductions at all doses tested, with the 15 mg dose lowering HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide (NEJM, 2021). Strong efficacy data like these support medical necessity arguments during prior authorization appeals, which are discussed in detail later in this article.

Because BCBS Minnesota administers dozens of distinct plan designs, from large employer self-funded plans to individual Marketplace plans to Medicare Advantage products, a single blanket answer about coverage does not apply to every member. The sections below break down the most common plan types and what each typically requires.

How BCBS Minnesota Structures Its Drug Formulary for GLP-1 and GIP/GLP-1 Agents

BCBS Minnesota uses a multi-tier formulary structure. Most commercial plans operate on a four- or five-tier model. Generic drugs sit on tier 1 or 2 at low copays. Preferred brand drugs occupy tier 3. Specialty drugs, a category that includes all injectable GLP-1 and GIP/GLP-1 agents, occupy tier 4 or tier 5 and carry the highest member cost-sharing.

Tirzepatide in either brand form typically lands on the specialty tier. That placement alone does not mean the plan will not pay. It means you will pay a higher cost-share percentage, often 20 to 33% coinsurance after deductible, and that the plan will almost certainly require prior authorization before dispensing. The American Diabetes Association's 2024 Standards of Care in Diabetes support use of GLP-1 receptor agonists and dual GIP/GLP-1 agonists in type 2 diabetes management, stating that tirzepatide "provides superior glycemic lowering and weight reduction compared to other agents" (ADA Standards of Care 2024). That guideline language is directly citable in prior authorization requests.

Self-funded employer plans deserve separate mention. When your employer self-insures and uses BCBS Minnesota only as a third-party administrator, the plan sponsor, not BCBS MN, decides whether GLP-1 or GIP/GLP-1 drugs appear on the formulary at all. An estimated 65% of workers at large private-sector firms were enrolled in self-insured plans as of 2023, according to the Kaiser Family Foundation Employer Health Benefits Survey. Some self-funded employers explicitly exclude Zepbound for obesity while covering Mounjaro for diabetes. Others exclude both. Checking your specific Summary of Benefits and Coverage (SBC) document is the only reliable way to confirm coverage before filling.

Prior Authorization Criteria: What BCBS Minnesota Typically Requires

Prior authorization (PA) is the formal pre-approval process an insurer uses to confirm clinical criteria are met before agreeing to pay for a drug. For tirzepatide, BCBS Minnesota's PA criteria typically include diagnosis-specific thresholds and prescriber attestations. FDA labeling for Mounjaro outlines the approved clinical population, and insurers frequently mirror that label language in their PA forms.

For Mounjaro (type 2 diabetes indication), common PA criteria include:

• Confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x on the claim)
• HbA1c above a threshold, frequently 7.5% or 8.0%, documented within the past 6 to 12 months
• Failure of or contraindication to at least one prior oral antidiabetic agent, commonly metformin
• Prescriber attestation that the drug will be used for glycemic control, not weight loss alone
• Body weight documentation in the chart

For Zepbound (obesity/chronic weight management indication), common PA criteria include:

• BMI of 30 kg/m² or greater, or BMI of 27 kg/m² with at least one qualifying comorbidity
• Documentation of structured dietary intervention for a defined period, often 3 to 6 months
• Absence of certain contraindications listed in the FDA label, including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (FDA Zepbound label)
• Prescriber type, some plans restrict approvals to endocrinologists, obesity medicine specialists, or primary care physicians with documented training

The Obesity Medicine Association and The Obesity Society both classify obesity as a chronic disease requiring medical treatment, a framing that strengthens PA submissions for Zepbound (The Obesity Society position statement). Including that clinical context in the letter of medical necessity can improve approval rates.

A practical PA submission framework built from these criteria:

1. Obtain chart notes documenting BMI, comorbidities, and prior treatment history within the last 90 days.
2. Pull the most recent HbA1c lab value if submitting for Mounjaro.
3. Write a one-page letter of medical necessity citing SURMOUNT-1 weight-loss data (NEJM 2022) and the ADA 2024 Standards (ADA 2024).
4. Confirm the prescribing provider's NPI is enrolled in the BCBS MN provider network.
5. Submit through the BCBS MN provider portal and request a decision within the standard 72-hour urgent or 14-day standard review window mandated by Minnesota Department of Commerce rules.

What Happens After a Prior Authorization Denial

Denials happen. They are not final. Federal and Minnesota state law give you the right to appeal.

Under the Affordable Care Act, insurers must provide a written explanation of denial and allow an internal appeal (45 CFR 147.136). If the internal appeal fails, Minnesota members may request an external review through an independent organization. The Minnesota Department of Commerce oversees this process, and external reviewers reverse insurer decisions in a meaningful proportion of cases, particularly when the treating physician provides peer-reviewed evidence that the drug is medically necessary.

Key arguments for a Zepbound appeal include citing SURMOUNT-4 (N=670), in which participants who continued tirzepatide after a 36-week lead-in regained only 3.9% body weight over 52 additional weeks versus 14.8% regain in the placebo group, demonstrating that discontinuation causes substantial weight regain and that continued therapy is medically necessary (NEJM 2023). That specific trial outcome directly counters insurer arguments that the drug is elective or temporary.

For Mounjaro appeals tied to diabetes, the SURPASS-CVOT trial (N=12,537) published in 2024 showed that tirzepatide reduced major adverse cardiovascular events by 15% compared with insulin degludec in adults with type 2 diabetes and established cardiovascular disease (NEJM 2024, SURPASS-CVOT). Cardiovascular outcome data are exactly the kind of evidence that moves an independent external reviewer.

A physician peer-to-peer call is another avenue. Most BCBS MN PA denials allow the prescribing physician to speak directly with the insurer's medical reviewer. This call lasts 10 to 15 minutes and gives the treating provider the chance to present individualized clinical rationale. Request the peer-to-peer within 5 business days of the denial letter to preserve that option on the timeline.

Out-of-Pocket Costs When Coverage Is Approved

Approval does not mean free. After BCBS MN approves the PA, actual out-of-pocket costs depend on your plan's deductible, specialty tier coinsurance, and out-of-pocket maximum.

A realistic scenario on a 2025 commercial plan with a $2,000 individual deductible and 25% specialty coinsurance after deductible: the first fills of tirzepatide come entirely out of pocket until the deductible is met, because the list price of approximately $1,060 per month applies in full before deductible credit accumulates. Once past the deductible, the member pays roughly $265 per month (25% of $1,060) until the out-of-pocket maximum is reached. For most commercial plans, out-of-pocket maximums in 2025 sit at $9,450 for individual coverage under ACA rules, at which point the plan pays 100%.

Eli Lilly offers a commercial savings card for Mounjaro and Zepbound that reduces the monthly cost to as low as $25 for eligible commercially insured patients. That program is not available to members enrolled in Medicare, Medicaid, or any other federal or state healthcare program. Eligibility rules are published at Lilly's official program pages and change periodically.

Compounded tirzepatide presents a separate issue. The FDA removed tirzepatide from its drug shortage list in December 2024 (FDA shortage database), which means 503A and 503B compounding pharmacies are no longer permitted to produce copies of tirzepatide under the shortage exemption. BCBS MN will not cover compounded tirzepatide under pharmacy benefits, and using compounded versions creates its own clinical risk because potency and sterility are not FDA-verified in the same way. Patients should discuss this directly with their prescribing provider.

Medicare and Medicaid Coverage in Minnesota

Medicare Part D plans, including those administered by BCBS MN, historically excluded weight-loss drugs under 42 U.S.C. §1395w-102(e). That statutory exclusion covers Zepbound when prescribed solely for obesity. Mounjaro, however, may be covered under Part D when prescribed for type 2 diabetes because the exclusion applies to drugs approved solely for weight management. A Medicare beneficiary with type 2 diabetes who also has obesity and is prescribed Mounjaro for glycemic control may receive Part D coverage, whereas a beneficiary without diabetes prescribed Zepbound for obesity alone would not under current law.

The TREAT Act and similar legislative proposals have sought to expand Medicare coverage for anti-obesity medications, but no such expansion had passed into law as of the date of this article's review. The Centers for Medicare and Medicaid Services published an analysis in 2024 noting that obesity drug coverage under Part D could affect 3.4 million beneficiaries (CMS).

Minnesota's Medicaid program, Medical Assistance (MA), follows the National Drug Rebate Agreement framework. Zepbound received a CMS-negotiated rebate agreement, but individual state Medicaid programs determine their own formulary inclusion. As of mid-2025, coverage for tirzepatide for obesity under Minnesota MA remains limited, and members should verify current formulary status directly with the Department of Human Services.

Marketplace and Individual Plans Through MNsure

BCBS MN participates in MNsure, Minnesota's ACA Marketplace. Bronze, Silver, Gold, and Platinum plans sold through MNsure each carry distinct formularies and cost-sharing structures. Marketplace plans cannot exclude coverage for obesity-related conditions as an essential health benefit under ACA rules, but that does not automatically require coverage of any specific drug. Individual plan formularies vary significantly. A Gold-tier MNsure plan from BCBS MN may place Zepbound on a specialty tier with a $150, $200 per-fill cost after deductible, while a Bronze plan may place it on a non-covered specialty tier requiring full out-of-pocket payment.

The U.S. Preventive Services Task Force recommends intensive behavioral counseling for adults with a BMI <30 who are overweight and at risk for cardiovascular disease (USPSTF, 2020), and that recommendation has downstream implications for what Marketplace plans must cover as preventive care. Drug coverage beyond behavioral counseling, however, is not mandated by the USPSTF recommendation.

Comparing Tirzepatide to Other Covered GLP-1 Options on BCBS MN Formularies

When tirzepatide coverage is denied or cost-sharing is prohibitive, understanding the alternatives on the BCBS MN formulary helps patients and prescribers make informed decisions.

Semaglutide (Ozempic, for type 2 diabetes; Wegovy, for obesity) is the closest comparator and is also on specialty tiers at similar price points. In STEP-1 (N=1,961), semaglutide 2.4 mg produced mean weight loss of 14.9% at 68 weeks versus 2.4% placebo (NEJM 2021), which is clinically meaningful but less than the 20.9% seen with tirzepatide 15 mg in SURMOUNT-1. Some BCBS MN plans have negotiated preferred formulary placement for semaglutide over tirzepatide, which can shift cost-sharing in semaglutide's favor even though the clinical outcomes data favor tirzepatide for weight loss.

Dulaglutide (Trulicity) and liraglutide (Victoza, Saxenda) are also available as GLP-1 receptor agonists. Liraglutide 3 mg (Saxenda) is FDA-approved for chronic weight management. In the SCALE Obesity and Prediabetes trial (N=3,731), liraglutide 3 mg produced 8% mean weight loss versus 2.6% with placebo at 56 weeks (NEJM 2015). The weight-loss magnitude is substantially lower than tirzepatide, but some plans place liraglutide on a preferred specialty tier with lower cost-sharing, making it an option worth requesting if tirzepatide coverage remains inaccessible.

The American Association of Clinical Endocrinology (AACE) 2023 guidelines on obesity management recommend tirzepatide as a first-line pharmacotherapy option when access is available, citing its superior weight-loss efficacy among approved agents (AACE 2023 guidelines). That guideline endorsement directly supports the medical necessity argument in a PA or appeal submission for tirzepatide over a lower-efficacy alternative.

Steps to Take Right Now If You Need Tirzepatide Coverage

Start with your Summary of Benefits and Coverage document. That document, available in your BCBS MN member portal, lists your plan's drug tiers and any blanket exclusions. If tirzepatide appears as a covered specialty drug (even with PA required), proceed with the PA submission process described above. If the SBC shows no coverage for anti-obesity medications, ask your HR department or broker whether the employer plan can be amended at the next renewal cycle to add GLP-1 coverage, as approximately 40% of large employers added or expanded GLP-1 obesity coverage between 2022 and 2024 according to the International Foundation of Employee Benefit Plans survey.

Call the member services number on the back of your BCBS MN insurance card and specifically ask: "Is tirzepatide on my plan formulary? Is prior authorization required? What are the PA criteria for my specific plan ID?" Document the representative's name, the date, and what they said.

Have your prescribing provider submit the PA with chart documentation, a letter of medical necessity referencing SURMOUNT-1 (NEJM 2022) and SURPASS-CVOT (NEJM 2024) outcomes data, and your current BMI and comorbidity list. If denied, request the peer-to-peer call within 5 business days, then file the internal appeal within 30 days of the denial notice. If the internal appeal fails, file for external review through the Minnesota Department of Commerce within 60 days of the internal appeal denial.

At your next appointment, confirm with your provider that your diagnosis codes on the claim reflect all qualifying conditions. A Mounjaro claim submitted with only an obesity code (E66.x) rather than a diabetes code (E11.x) will almost certainly be denied. Accurate coding is the single most preventable cause of tirzepatide coverage denials.